Validation of a transparent decision model to rate drug interactions

BMC Pharmacology and Toxicology

Volumn 13, Issue , 2012, Pages

  Far, Elmira ^a   Curkovic, Ivanka ^a   Byrne, Kelly ^a   Roos, Malgorzata ^b   Egloff, Isabelle ^a   Dietrich, Michael ^c   Kirch, Wilhelm ^d   Kullak Ublick, Gerd A ^a   Egbring, Marco ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c BALGRIST UNIVERSITY HOSPITAL   (Switzerland)

^d DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Algorithm; Decision; Drug; Epha.ch; Interaction; Mmx; Model; Severity; Validation

Indexed keywords

ROXITHROMYCIN; SIMVASTATIN;

ALGORITHM; ARTICLE; DATA BASE; DRUG INTERACTION; HUMAN; PHARMACIST; PHYSICIAN; PRACTICE GUIDELINE; VALIDATION STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DECISION SUPPORT SYSTEM; DRUG DATABASE; DRUG SURVEILLANCE PROGRAM; RANDOMIZED CONTROLLED TRIAL; REPRODUCIBILITY; STANDARD; STATISTICAL MODEL; STATISTICS;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ALGORITHMS; DATABASES, PHARMACEUTICAL; DECISION SUPPORT TECHNIQUES; DRUG INTERACTIONS; MODELS, STATISTICAL; PHARMACISTS; REPRODUCIBILITY OF RESULTS;

MLCS; MLOWN;

EID: 84879737584     PISSN: 20506511     EISSN: None     Source Type: Journal    
DOI: 10.1186/2050-6511-13-7     Document Type: Article

References (30)

1. Bates DW, Spell N, Cullen DJ, Burdick E, Laird N, Petersen LA, Small SD, Sweitzer BJ, Leape LL. The costs of adverse drug events in hospitalized patients. Adverse Drug Events Prevention Study Group. JAMA 1997, 277(4):307-311. 10.1001/jama.1997.03540280045032, 9002493.
2. Juurlink D, Mamdani M, Iazzetta J, Etchells E. Avoiding drug interactions in hospitalized patients. Healthc Q 2004, 7(2):27-28.
3. Krahenbuhl-Melcher A, Schlienger R, Lampert M, Haschke M, Drewe J, Krahenbuhl S. Drug-related problems in hospitals: a review of the recent literature. Drug safety: an international journal of medical toxicology and drug experience 2007, 30(5):379-407.
4. Zwart-van Rijkom JE, Uijtendaal EV, ten Berg MJ, van Solinge WW, Egberts AC. Frequency and nature of drug-drug interactions in a Dutch university hospital. Br J Clin Pharmacol 2009, 68(2):187-193. 10.1111/j.1365-2125.2009.03443.x, 2767281, 19694737.
5. Bates DW, Leape LL, Cullen DJ, Laird N, Petersen LA, Teich JM, Burdick E, Hickey M, Kleefield S, Shea B, et al. Effect of computerized physician order entry and a team intervention on prevention of serious medication errors. JAMA 1998, 280(15):1311-1316. 10.1001/jama.280.15.1311, 9794308.
6. Garg AX, Adhikari NK, McDonald H, Rosas-Arellano MP, Devereaux PJ, Beyene J, Sam J, Haynes RB. Effects of computerized clinical decision support systems on practitioner performance and patient outcomes: a systematic review. JAMA 2005, 293(10):1223-1238. 10.1001/jama.293.10.1223, 15755945.
7. Hansten PD, Horn JR, Hazlet TK. ORCA: Operational Classification of drug interactions. J Am Pharm Assoc (Wash) 2001, 41(2):161-165.
8. Bergk V, Gasse C, Rothenbacher D, Loew M, Brenner H, Haefeli WE. Drug interactions in primary care: impact of a new algorithm on risk determination. Clin Pharmacol Ther 2004, 76(1):85-96. 10.1016/j.clpt.2004.02.009, 15229467.
9. Guzek MZO, Semmler A, Gonzenbach R, Huber M, Kullak-Ublick GA, Weller M, Russmann S. Evaluation of Drug Interactions and Dosing in 484 Neurological Inpatients Using Clinical Decision Support Software and an Extended Operational Interactions Classification System (ZHIAS). Pharmacoepidemiol Drug Saf 2011, in press.
10. Frolich T, Zorina O, Fontana AO, Kullak-Ublick GA, Vollenweider A, Russmann S. Evaluation of medication safety in the discharge medication of 509 surgical inpatients using electronic prescription support software and an extended operational interaction classification. Eur J Clin Pharmacol 2011, 67(12):1273-1282. 10.1007/s00228-011-1081-9, 21671021.
11. Vitry AI. Comparative assessment of four drug interaction compendia. Br J Clin Pharmacol 2007, 63(6):709-714. 10.1111/j.1365-2125.2006.02809.x, 2000587, 17166171.
12. Chan A, Tan SH, Wong CM, Yap KY, Ko Y. Clinically significant drug-drug interactions between oral anticancer agents and nonanticancer agents: a Delphi survey of oncology pharmacists. Clin Ther 2009, 31(Pt 2):2379-2386.
13. Olvey EL, Clauschee S, Malone DC. Comparison of critical drug-drug interaction listings: the Department of Veterans Affairs medical system and standard reference compendia. Clin Pharmacol Ther 2010, 87(1):48-51. 10.1038/clpt.2009.198, 19890252.
14. Fulda TR. Disagreement among drug compendia on inclusion and ratings of drug-drug interactions. Curr Ther Res 2000, 61(8):540-548.
15. Horn JR. Reducing Drug Interactions Alerts: Not So Easy Available at http://www.hanstenandhorn.com/hh-article06-07.pdf.
16. Drug-Reax System Micromedex Healthcare Series (database on CD-ROM) Version 5.1 2007, Thomson Reuters (Healthcare) Inc, Greenwood Village, Colorado, Drug-Reax System.
17. Pharmavista Interactions 2010, Available at: http://www.pharmavista.ch, Pharmavista Interactions.
18. Drug Interactions Analysis and Management 2011, Facts & Comparisons, St.Louis, MO, Hansten PD, Horn JR.
19. Stockley's drug interactions 2009, Pharmaceutical Press, London, Baxter K, 8.
20. Tollefson G, Lesar T, Grothe D, Garvey M. Alprazolam-related digoxin toxicity. Am J Psychiatry 1984, 141(12):1612-1613.
21. Ochs HR, Greenblatt DJ, Verburg-Ochs B. Effect of alprazolam on digoxin kinetics and creatinine clearance. Clin Pharmacol Ther 1985, 38(5):595-598. 10.1038/clpt.1985.230, 2865030.
22. Hansten PD. Drug interaction management. Pharm World Sci 2003, 25(3):94-97. 10.1023/A:1024077018902, 12840961.
23. Isaac T, Weissman JS, Davis RB, Massagli M, Cyrulik A, Sands DZ, Weingart SN. Overrides of medication alerts in ambulatory care. Arch Intern Med 2009, 169(3):305-311. 10.1001/archinternmed.2008.551, 19204222.
24. Smithburger PL, Buckley MS, Bejian S, Burenheide K, Kane-Gill SL. A critical evaluation of clinical decision support for the detection of drug-drug interactions. Expert Opin Drug Saf 2011, 10(6):871-882. 10.1517/14740338.2011.583916, 21542665.
25. van Roon EN, Flikweert S, le Comte M, Langendijk PN, Kwee-Zuiderwijk WJ, Smits P, Brouwers JR. Clinical relevance of drug-drug interactions: a structured assessment procedure. Drug safety: an international journal of medical toxicology and drug experience 2005, 28(12):1131-1139.
26. Altman D. Practical statistics for medical research 1991, Chapman & Hall, London.
27. Wilson EB. Probable inference, the law of succession, and statistical inference. JASA 1927, 22:209-212.
28. Larkin JH, Simon HA. Why a Diagram is (Sometimes) Worth Ten Thousand Words. Cogn Sci 1987, 11(1):65-100.
29. Weingart SN, Seger AC, Feola N, Heffernan J, Schiff G, Isaac T. Electronic drug interaction alerts in ambulatory care: the value and acceptance of high-value alerts in US medical practices as assessed by an expert clinical panel. Drug safety: an international journal of medical toxicology and drug experience 2011, 34(7):587-593.
30. Seidling HM, Phansalkar S, Seger DL, Paterno MD, Shaykevich S, Haefeli WE, Bates DW. Factors influencing alert acceptance: a novel approach for predicting the success of clinical decision support. Journal of the American Medical Informatics Association: JAMIA 2011, 18(4):479-484. 10.1136/amiajnl-2010-000039, 3128393, 21571746.